Suche klinische Studie
Weitere Suchoptionen
8 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younger with Cryopyrin Associated Periodic Syndromes (CAPS) (Phase III) - FR
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
PARIS
COLCHI-RESIST: Study Of Colchicine Resistance In Familial Mediterranean Fever.
Groupe hospitalier AP-HP.6 - Hôpital Tenon
Service de médecine interne
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever
Institution: Information not provided - JP
DEUTSCHLAND
Berlin
BERLIN
LANA-FXII: Faktor XII-assoziiertes autoinflammatorisches Kälte-Syndrom (FACAS) in Verbindung mit Kallikrein-Kinin-Pathologie: Wirksamkeitsnachweis der Behandlung mit Lanadelumab (DX-2930)
Charité - Universitätsmedizin Berlin (CCM)
Autoinflammation Reference Center Charité (ARC²)
Multinationale klinische Studie(n)
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) (Phase III) (Coordination)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (Phase III)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long-term treatment period in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS)
Institution: Information not provided - CH
VEREINIGTE STAATEN
Pennsylvania
PHILADELPHIA